NPI: 1699743195 · ORANGE CITY, FL 32763 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/09/2006
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 03/09/2006 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 6,045 | $543K |
| 2019 | 10,397 | $1.04M |
| 2020 | 7,380 | $2.35M |
| 2021 | 408 | $53K |
| 2022 | 1,136 | $303K |
| 2023 | 528 | $77K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 9,645 | 749 | $1.63M |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 8,069 | 370 | $1.35M |
| J1270 | Injection, doxercalciferol, 1 mcg | 4,732 | 376 | $741K |
| A4657 | Syringe, with or without needle, each | 835 | 488 | $211K |
| J1756 | Injection, iron sucrose, 1 mg | 884 | 203 | $162K |
| 85041 | 320 | 250 | $57K | |
| 85048 | 317 | 249 | $57K | |
| 85045 | 275 | 203 | $47K | |
| 83970 | 209 | 166 | $38K | |
| 82728 | 156 | 128 | $26K | |
| 83540 | 139 | 115 | $19K | |
| 83550 | 139 | 115 | $19K | |
| 82108 | 111 | 90 | $12K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 32 | 25 | $4K |
| 82607 | 16 | 13 | $2K | |
| 82746 | 15 | 12 | $2K |